On Friday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $49.25 which represents a decrease of $-0.05 or -0.10% from the prior close of $49.3. The stock opened at $49.35 ...
Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) yesterday and set a price target of ...
Halozyme is relatively low-beta and an ideal stock in the biotech sector for a covered call trade with good liquidity on ...
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Halozyme (HALO – Research Report) and keeping the price target at ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and ...
Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2024 $17.5 Call had some of the highest ...
On Monday, Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $51.77 which represents a decrease of $-0.84 or -1.60% from the prior close of $52.61. The stock opened at $52.6 ...
Zacks.com on MSN9d
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-TermTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 821,620 shares ...
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a ...
San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback